

Triterpenoids from the Roots of *Camellia oleifera* C.ABEL and Their Cytotoxic Activities

by Shou-Li Wang^a), Zhong Chen^b), Xiao-Jing Tong^b), Yan-Li Liu^b), Xia Li^b), Qiong-Ming Xu^{*b}), Xiao-Ran Li^b), and Shi-Lin Yang^b)


^a) College of Medicine, Soochow University, Suzhou 215123, P. R. China

^b) College of Pharmaceutical Science, Soochow University, Suzhou 215123, P. R. China
(phone: +86-512-69561421; fax: +86-512-65882089; e-mail: xuqiongming@suda.edu.cn)

Three new triterpenoids, 21 β ,22 α -diangeloyloxy-3 β ,15 α ,16 α ,28-tetrahydroxyolean-12-en-23-al (**1**), 21 β -angeloyloxy-3 β ,15 α ,16 α ,28-tetrahydroxy-22 α -(2-methylbutanoyloxy)olean-12-en-23-al (**2**), and 21 β -angeloyloxy-3 β ,16 α ,28-trihydroxy-22 α -(2-methylbutanoyloxy)olean-12-en-23-al (**3**), along with six known triterpenoids, were isolated from the roots of *Camellia oleifera* C.ABEL. The structures of compounds **1–3** were elucidated on the basis of spectroscopic analyses. Moreover, all compounds isolated were evaluated for their cytotoxic activities by MTT (= 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay.

Introduction. – *Camellia oleifera* C.ABEL has been grown as an oil crop in many countries including China, Brazil, Philippines, India, and South Korea. The roots of *C. oleifera* is also well-known as traditional Chinese medicine used for treatment of common cold, bovine fever, ardent fever, urinary tract infection, nephritis, edema, unpeaceful quickening, and threatened abortion [1]. Previous studies on constituents from the *Camellia* genus led to the isolation of different compounds such as flavones, triterpenoids, and its glycosides [2][3]. During the course of our investigation for cytotoxic agents from the EtOH extract of the roots of *C. oleifera*, three new triterpenoids, 21 β ,22 α -diangeloyloxy-3 β ,15 α ,16 α ,28-tetrahydroxyolean-12-en-23-al (**1**), 21 β -angeloyloxy-3 β ,15 α ,16 α ,28-tetrahydroxy-22 α -(2-methylbutanoyloxy)olean-12-en-23-al (**2**), 21 β -angeloyloxy-3 β ,16 α ,28-trihydroxy-22 α -(2-methylbutanoyloxy)olean-12-en-23-al (**3**), were isolated from the roots of *C. oleifera*, along with six known triterpenoids, 21 β ,22 α -diangeloyloxy-3 β ,16 α ,28-trihydroxyolean-12-en-23-al (**4**) [4], 21 β ,22 α -diangeloyloxy-3 β ,15 α ,16 α ,28-tetrahydroxyolean-12-ene (**5**) [5], 21 β -angeloyloxy-3 β ,15 α ,16 α ,28-tetrahydroxy-22 α -(2-methylbutanoyloxy)olean-12-ene (**6**) [6], 21 β ,22 α -diangeloyloxy-3 β ,16 α ,28-trihydroxyolean-12-ene (**7**) [7], 21 β -angeloyloxy-3 β ,16 α ,28-trihydroxy-22 α -(2-methylbutanoyloxy)olean-12-ene (**8**) [8], and 22 α -angeloyloxy-3 β ,15 α ,16 α ,28-tetrahydroxyolean-12-ene (**9**) [9] (Fig. 1). Herein, we report the isolation and structure elucidation of the new compounds **1–3**, as well as their cytotoxic activities.

Results and Discussion. – Compound **1** was isolated as a white powder. Its molecular formula was deduced as C₄₀H₆₀O₉ on the basis of the positive-ion-mode HR-ESI-MS, *m/z* 707.4113 ([*M* + Na]⁺) and a comprehensive analysis of the NMR data.

Fig. 1. Structures of compounds **1–9**

The IR spectrum indicated the presence of OH groups (3452 cm^{-1}), an CHO group ($2818, 2719, 1739\text{ cm}^{-1}$), and two α,β -unsaturated ester C=O groups (1605 and 1602 cm^{-1}). The ^{13}C -NMR spectrum (Table 1) exhibited resonances for 40 C-atoms, substitution patterns of which were deduced from DEPT and HSQC experiments as ten Me, seven CH_2 , and eleven CH groups, and twelve quaternary C-atoms. It showed signals of five O–CH C-atoms at $\delta(\text{C})$ 72.1, 67.6, 72.0, 78.5, and 73.4, corresponding to C(3), C(15), C(16), C(21), and C(22), respectively, as well as one OCH_2 signal at $\delta(\text{C})$ 63.2, corresponding to C(28) and one CHO signal at $\delta(\text{C})$ 208.4, corresponding to C(23). The ^1H -NMR spectrum (Table 1) displayed six signals at $\delta(\text{H})$ 1.48 (*s*, 3 H), 1.09 (*s*, 3 H), 1.08 (*s*, 3 H), 1.01 (*s*, 3 H), 0.98 (*s*, 3 H), and 0.92 (*s*, 3 H), which were assigned to six tertiary Me groups. An olefinic H-atom signal at $\delta(\text{H})$ 5.51 (*t*, $J = 4.0$, H–C(12)), a CH signal at $\delta(\text{H})$ 3.70 (*dd*, $J = 11.0, 4.5$, H–C(3)), an CHO signal at $\delta(\text{H})$ 9.42 (*s*, H–C(23)), and signals of a $\text{CH}_2\text{–O}$ group at $\delta(\text{H})$ 3.30, 2.99 (*2d*, $J = 12.0$, $\text{CH}_2(28)$) suggested that compound **1** belongs to the olean-12-ene-type pentacyclic triterpene family. Its ^1H -NMR spectrum also exhibited signals of two angeloyl (=2-methylbut-2-enoyl; Ang) groups at $\delta(\text{H})$ (6.05 (*dq*, $J = 7.0, 1.5$, H–C(3'), 21-*O*-Ang), 1.94 (*d*, $J = 7.0$, Me(4'), 21-*O*-Ang), 1.83 (*d*, $J = 1.5$, Me(5'), 21-*O*-Ang)), and 6.08 (*dq*, $J = 7.0, 1.5, 1\text{ H}$, 22-*O*-Ang-3''), 1.94 (*d*, $J = 7.0$, Me(4''), 22-*O*-Ang), 1.83 (*d*, $J = 1.5$, Me(5''), 22-*O*-Ang). The two AngO groups were located at C(21) and C(22) on the basis of the downfield shifts of H–C(21) at $\delta(\text{H})$ 5.87 (*d*, $J = 10.5$) and H–C(22) at $\delta(\text{H})$ 5.44 (*d*, $J = 10.5$), which was supported by the correlation between $\delta(\text{H})$ 5.87 (*d*, $J = 10.5$, H–C(21)) and $\delta(\text{C})$ 168.9 (C(1')21-*O*-Ang), as well as the correlation between $\delta(\text{H})$ 5.44 (*d*, $J = 10.5$, H–C(22)) and $\delta(\text{C})$ 169.8 (C(1'')22-*O*-Ang) in the HMBC spectrum (Fig. 2).

The relative configuration of compound **1** was established from its NOESY spectrum (Fig. 3). The cross-peaks between H–C(21) ($\delta(\text{H})$ 5.87) and Me(29) ($\delta(\text{H})$ 0.92), as well as those between H–C(22) (5.44) and Me(30) (1.09), and $\text{CH}_2(28)$ (3.30 and 2.99), suggested that H–C(21) and H–C(22) are α - and β -oriented, respectively. The H–C(15) ($\delta(\text{H})$ 3.76) correlated with $\text{CH}_2(28)$ (3.30 and 2.99) and H–C(18) (2.65), indicating that the 15-OH group is α -configured. In addition, the small coupling constant ($J(15,16) = 4.5$) suggested that H–C(15) is axial and H–C(16) is equatorial.

Table 1. ^1H - and ^{13}C -NMR (500 and 125 MHz, resp.) Data of Compounds **1–3**. In CDCl_3 ; δ in ppm, J in Hz. For atom numbering, cf. Fig. 2.

Position	1		2		3	
	$\delta(\text{H})$	$\delta(\text{C})$	$\delta(\text{H})$	$\delta(\text{C})$	$\delta(\text{H})$	$\delta(\text{C})$
1	1.69–1.72 (<i>m</i>), 1.08–1.10 (<i>m</i>)	39.1	1.71–1.74 (<i>m</i>), 1.05–1.09 (<i>m</i>)	38.3	1.75–1.76 (<i>m</i>), 1.09–1.13 (<i>m</i>)	38.2
2	1.71–1.75 (<i>m</i>), 1.10–1.25 (<i>m</i>)	26.4	1.71–1.73 (<i>m</i>), 1.68–1.70 (<i>m</i>)	26.1	1.71–1.74 (<i>m</i>), 1.64–1.66 (<i>m</i>)	26.2
3	3.70 (<i>dd</i> , $J=11.0, 4.5$)	72.1	3.70 (<i>dd</i> , $J=11.0, 4.5$)	71.7	3.82 (<i>dd</i> , $J=11.0, 4.5$)	71.9
4		56.2		55.1		55.2
5	0.78 (<i>d</i> , $J=10.5$)	48.5	0.78 (<i>d</i> , $J=10.5$)	48.2	0.78 (<i>d</i> , $J=10.5$)	48.2
6	1.42–1.61 (<i>m</i>), 1.10–1.25 (<i>m</i>)	20.6	1.53–1.57 (<i>m</i>), 1.14–1.26 (<i>m</i>)	20.9	1.57–1.59 (<i>m</i>), 1.15–1.26 (<i>m</i>)	20.7
7	1.74–1.77 (<i>m</i>), 1.63–1.67 (<i>m</i>)	35.7	1.75–1.77 (<i>m</i>), 1.63–1.66 (<i>m</i>)	35.8	1.71–1.74 (<i>m</i>), 1.59–1.61 (<i>m</i>)	32.2
8		40.7		41.3		40.1
9	1.26 (<i>d</i> , $J=12.5$)	47.3	1.26 (<i>d</i> , $J=12.5$)	47.1	1.26 (<i>d</i> , $J=12.5$)	46.5
10		36.5		35.9		35.9
11	1.92–1.95 (<i>m</i>), 1.41–1.63 (<i>m</i>)	24.2	1.86–1.93 (<i>m</i>), 1.42–1.53 (<i>m</i>)	23.6	1.86–1.99 (<i>m</i>), 1.42–1.53 (<i>m</i>)	23.5
12	5.51 (<i>t</i> , $J=4.0$)	126.3	5.53 (<i>t</i> , $J=4.0$)	125.9	5.46 (<i>t</i> , $J=4.0$)	124.4
13		142.5		141.6		140.9
14		48.1		47.9		41.2
15	3.76 (<i>d</i> , $J=4.5$)	67.6	3.72 (<i>d</i> , $J=4.5$)	67.5	1.66–1.68 (<i>m</i>), 1.35–1.40 (<i>m</i>)	33.6
16	3.78 (<i>d</i> , $J=4.5$)	72	3.74 (<i>d</i> , $J=4.5$)	73.4	3.94 (<i>t</i> , $J=4.0$)	69.6
17		47.7		46.6		47.8
18	2.65 (<i>dd</i> , $J=14.0, 4.0$)	40.7	2.71 (<i>dd</i> , $J=14.0, 4.0$)	39.8	2.72 (<i>dd</i> , $J=14.0, 4.0$)	39.3
19	1.98–2.60 (<i>m</i>), 1.75–1.77 (<i>m</i>)	47.3	2.52–2.90 (<i>m</i>), 1.75–1.78 (<i>m</i>)	45.9	2.52–2.90 (<i>m</i>), 1.75–1.77 (<i>m</i>)	46.4
20		36.3		35.3		35.8
21	5.87 (<i>d</i> , $J=10.5$)	78.5	5.76 (<i>d</i> , $J=10.5$)	77.3	5.82 (<i>d</i> , $J=10.5$)	77.3
22	5.44 (<i>d</i> , $J=10.5$)	73.4	5.32 (<i>d</i> , $J=10.5$)	73.3	5.41 (<i>d</i> , $J=10.5$)	73.2
23	9.42 (<i>s</i>)	208.4	9.41 (<i>s</i>)	207	9.42 (<i>s</i>)	207.1
24	1.08 (<i>s</i>)	9.3	1.08 (<i>s</i>)	9	1.08 (<i>s</i>)	9
25	1.01 (<i>s</i>)	16.4	1.00 (<i>s</i>)	15.8	1.01 (<i>s</i>)	15.9
26	0.98 (<i>s</i>)	17.6	0.98 (<i>s</i>)	17.2	0.92 (<i>s</i>)	16.8
27	1.48 (<i>s</i>)	21.4	1.42 (<i>s</i>)	20.3	1.48 (<i>s</i>)	27.1
28	3.30 (<i>d</i> , $J=12.0$), 2.99 (<i>d</i> , $J=12.0$)	63.2	3.28 (<i>d</i> , $J=12.0$), 2.93 (<i>d</i> , $J=12.0$)	62.6	3.26 (<i>d</i> , $J=12.0$), 2.98 (<i>d</i> , $J=12.0$)	63.6
29	0.92 (<i>s</i>)	29.5	0.92 (<i>s</i>)	28.9	0.94 (<i>s</i>)	29
30	1.09 (<i>s</i>)	20	1.09 (<i>s</i>)	19.5	1.09 (<i>s</i>)	19.6
1'		168.9		168.9		167.4
2'		127.8		127.8		127.4
3'	6.05 (<i>dq</i> , $J=7.0, 1.5$)	140.2	6.13 (<i>dq</i> , $J=7.0, 1.5$)	140.2	6.01 (<i>dq</i> , $J=7.0, 1.5$)	139.2
4'	1.94 (<i>d</i> , $J=7.0$)	16.1	1.93 (<i>d</i> , $J=7.0$)	16.1	1.96 (<i>d</i> , $J=7.0$)	15.9
5'	1.83 (<i>d</i> , $J=1.5$)	20.9	1.83 (<i>d</i> , $J=1.5$)	20.9	1.86 (<i>d</i> , $J=1.5$)	20.7
1''		169.8		178.7		178.8
2''		128.4	2.33–2.55 (<i>m</i> , 1 H)	41.3	2.33–2.36 (<i>m</i> , 1 H)	41.1
3''	6.08 (<i>dq</i> , $J=7.0, 1.5$)	139.1	1.59–1.62 (<i>m</i>), 1.15–1.26 (<i>m</i>)	26.6	1.61–1.64 (<i>m</i>), 1.15–1.26 (<i>m</i>)	26.7
4''	1.94 (<i>d</i> , $J=7.0$)	16.1	0.86 (<i>t</i> , $J=7.5$)	11.8	0.86 (<i>t</i> , $J=7.5$)	11.8
5''	1.83 (<i>d</i> , $J=1.5$)	20.9	1.05 (<i>d</i> , $J=6.7$)	16.4	1.04 (<i>d</i> , $J=6.7$)	16.5




Fig. 2. Key HMBCs of compounds **1–3**

The CHO group was established at position 23, which was confirmed by the correlation between H–C(23) at $\delta(\text{H})$ 9.42 (*s*, 1 H) and C(3) at $\delta(\text{C})$ 72.1 in the HMBC spectrum (Fig. 2), and the correlation between H–C(3) at $\delta(\text{H})$ 3.70 (*dd*, $J = 11.0, 4.5$) and H–C(23) at $\delta(\text{H})$ 9.42 (*s*, 1 H), as well as the correlation between Me(24) at $\delta(\text{H})$ 1.08 (*s*) and Me(25) at $\delta(\text{H})$ 1.01 (*s*) in the NOESY spectrum (Fig. 3). Thus, the structure of compound **1** was elucidated as 21 β ,22 α -diangeloyloxy-3 β ,15 α ,16 α ,28-tetrahydroxyolean-12-en-23-al.

Compound **2** was also obtained as a white powder. Its molecular formula was deduced as $\text{C}_{40}\text{H}_{62}\text{O}_9$ on the basis of the positive-ion-mode HR-ESI-MS (m/z 709.4270 ($[M + \text{Na}]^+$)) and the comprehensive analysis of the NMR data. The IR spectrum indicated the presence of OH groups (3475 cm^{-1}), an CHO group ($2820, 2719, 1742\text{ cm}^{-1}$), a C=O group (1720 cm^{-1}), and an α,β -unsaturated ester C=O group (1600 cm^{-1}). Compound **2** has a similar structure as compound **1**, which was confirmed by comparison of their ^1H - and ^{13}C -NMR spectra, the main differences arising from the signals at $\delta(\text{C})$ 178.7, 41.3, 26.6, 11.8, and 16.4 due to a 2-methylbutanoyl (MB) group in compound **2**. The angeloyl group is located at C(21) on the basis of the downfield shifts of C(21) at $\delta(\text{C})$ 77.3, which was supported by the correlation between $\delta(\text{H})$ 5.76 (*d*, $J = 10.5$, H–C(21)) and $\delta(\text{C})$ 168.9 (C(1'), 21-*O*-Ang) in the HMBC spectrum (Fig. 2). On the other hand, the 2-MBO group was established at C(22) on the basis of the downfield shift of C(22) at $\delta(\text{C})$ 73.3, which was supported by the correlation between $\delta(\text{H})$ 5.32 (*d*, $J = 10.5$, H–C(22)) and $\delta(\text{C})$ 178.7 (C(1''), 22-*O*-MB) in the HMBC spectrum (Fig. 2).




Fig. 3. Key NOESY correlations of compounds **1–3**

The relative configuration of compound **2** was further substantiated by its NOESY spectrum (Fig. 3). The cross-peaks between H–C(21) ($\delta(\text{H})$ 5.76) and Me(29) (0.92), as well as between H–C(22) (5.32) and Me(30) (1.09), and CH₂(28) (3.28 and 2.93), indicated that H–C(21) and H–C(22) are α - and β -oriented, respectively. The H–C(15) ($\delta(\text{H})$ 3.72) correlated with CH₂(28) (3.28 and 2.93), indicating that the 15-OH group is α -configured. In addition, the small coupling constant ($J(15,16) = 4.5$) suggested that H–C(15) is axial and H–C(16) is equatorial. Thus, the structure of compound **2** was elucidated as *21* β -angeloyloxy-*3* β ,*15* α ,*16* α ,*28*-tetrahydroxy-*22* α -(2-methylbutanoyloxy)olean-12-en-23-al.

Compound **3** was also obtained as a white powder. Its molecular formula was deduced as C₄₀H₆₂O₈ on the basis of the positive-ion-mode HR-ESI-MS (m/z 693.4316

($[M + Na]^+$) and the comprehensive analysis of the NMR data. The IR spectrum indicated the presence of OH groups (3450 cm^{-1}), an CHO group ($2820, 2720, 1738\text{ cm}^{-1}$), a C=O group (1722 cm^{-1}), and an α,β -unsaturated ester C=O groups (1603 cm^{-1}). Compound **3** had a similar structure as compound **4**, which was confirmed by comparison of their ^1H - and ^{13}C -NMR spectra, the main difference again arising from the presence of a 2-MB group in compound **3**. The AngO group was placed at C(21) on the basis of the downfield shifts of C(21) at $\delta(\text{C}) 77.3$, which was supported by the correlation between $\delta(\text{H}) 5.82$ ($d, J = 10.5, \text{H}-\text{C}(21)$) and $\delta(\text{C}) 167.4$ (C(1'), 21-*O*-Ang) in the HMBC spectrum (Fig. 2). The 2-MBO group was established at C(22) on the basis of the downfield shifts of C(22) at $\delta(\text{C}) 73.2$, which was supported by the correlation between $\delta(\text{H}) 5.41$ ($d, J = 10.5, \text{H}-\text{C}(22)$) and $\delta(\text{C}) 178.8$ (C(1''), 22-*O*-MB-1'') in the HMBC spectrum (Fig. 2).

The relative configuration of compound **3** was further substantiated by its NOESY spectrum (Fig. 3). The cross-peaks between H-C(21) ($\delta(\text{H}) 5.82$) and Me(29) (0.94), as well as between H-C(22) (5.41) and Me(30) (1.09), and $\text{CH}_2(28)$ (3.26 and 2.98), suggested that H-C(21) and H-C(22) are α - and β -oriented, respectively. The H-C(16) ($\delta(\text{H}) 3.94$) correlated with $\text{CH}_2(28)$ (3.26 and 2.98) and H-C(18) (2.72), indicating that the 16-OH group is α -configured. Thus, the structure of compound **3** was elucidated as 21 β -angeloyloxy-3 β ,16 α ,28-trihydroxy-22 α -(2-methylbutanoyloxy)olean-12-en-23-al.

Cytotoxic activities of the isolated compounds **1–9** were tested by MTT (= 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*-tetrazolium bromide) assay *in vitro* and expressed as IC_{50} values. They all exhibited moderate cytotoxic activities against human HeLa, SMMC-7721, and HL-60 tumor cell lines, with IC_{50} values ranging from 25.77 to 44.38 μM (Table 2). Preliminary analysis of the structure–activity relationship of these natural triterpenoids revealed that compounds **1**, **4**, and **7** with 21 β ,22 α -diangeloyloxy groups, exhibited slightly increased cytotoxic activities. Our results suggested that triterpenoids might be, at least in part, responsible for the proposed therapeutic effect of the roots of *C. oleifera*.

Table 2. *In vitro* Cytotoxic Activities of Triterpenoids **1–9** from the Roots of *Camellia oleifera*

Compound	IC_{50} [μM]		
	HeLa	SMMC-7721	HL-60
1	25.77 \pm 2.35	28.55 \pm 2.18	27.02 \pm 2.36
2	32.53 \pm 2.20	31.09 \pm 2.85	31.24 \pm 2.72
3	33.17 \pm 2.62	36.26 \pm 1.98	38.37 \pm 2.56
4	27.48 \pm 2.82	27.40 \pm 2.19	26.85 \pm 3.02
5	40.70 \pm 2.76	44.38 \pm 3.35	40.72 \pm 2.89
6	34.95 \pm 3.18	38.57 \pm 1.88	36.92 \pm 2.72
7	26.72 \pm 2.13	25.94 \pm 2.64	26.83 \pm 2.30
8	30.08 \pm 2.52	30.18 \pm 2.16	32.33 \pm 2.88
9	32.39 \pm 2.84	27.93 \pm 1.96	30.62 \pm 2.66
Norcantharidin	4.16 \pm 0.37	5.23 \pm 0.42	3.45 \pm 0.26

We are grateful to Prof. *Xue-Dong Yang* at the Department of Pharmaceutical Science and Technology, Tianjin University, for the HR-ESI-MS recording, and Mrs. *Li-Ping Shi* at the

Instrumentation Center of Shanghai Institute of Organic Chemistry, Chinese Academy of Science for the NMR recordings. This work was funded by the *Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)*.

Experimental Part

General. TLC: Precoated silica gel plates (SiO₂; *Qingdao Marine Chemical Factory*, Qingdao, China); visualized by 10% H₂SO₄ alcohol soln. Column chromatography (CC): SiO₂ (400–600 mesh; *Qingdao Marine Chemical Factory*, Qingdao, China). Medium pressure liquid chromatography (MPLC): ODS column (460 mm × 26 mm i.d., *Büchi Borosilikat 4.6*, CH-Flawil). Semi-prep. HPLC: ODS column (250 × 20 mm i.d., 5 μm *PRC-ODS* column; *Shimadzu Co., Ltd.*) with a *Waters 2996* detector; flow rate, 2 ml/min, and the wavelength for detection, 254 nm. Optical rotation: *Perkin-Elmer model 241* polarimeter. IR Spectra: *Perkin-Elmer 983G* spectrometer; $\tilde{\nu}$ in cm⁻¹. ¹H-, ¹³C-, and 2D-NMR spectra: *Varian Inova 500* spectrometer; in CDCl₃; δ in ppm rel. to Me₄Si as internal standard, *J* in Hz. HR-ESI-MS: *Micromass Q-TOF2* spectrometer; in *m/z*.

Plant Material. The roots of *Camellia oleifera* C. ABEL were collected in Hubei Province of China in November 2006, and identified by X.-R. L. of our college. A voucher sample (No. 06-11-06-01) is deposited with the Herbarium of the College of Pharmacy, Soochow University.

Extraction and Isolation. The dried plant material (10 kg) was percolated with 150 l of EtOH. The solvent was subsequently dried under reduced pressure to give the residue, which was partitioned between CHCl₃ and H₂O. The CHCl₃-soluble fraction was further partitioned between petroleum ether (PE) and 90% MeOH. The 90% MeOH fraction (26 g) was then subjected to MPLC (SiO₂; PE/AcOEt 10:90, 15:85, 20:80, 25:75, 30:70, 40:60, 50:50, 100:0, each 500 ml, at 5 ml/min) to afford eight fractions, *Fr.* 1–8. *Fr.* 2 (500–1000 ml, 303 mg) was isolated by semi-prep. HPLC (*PRC-ODS*; MeOH/H₂O 90:10, at 2 ml/min) to yield compounds *21β,22α-diangeloyloxy-3β,16α,28-trihydroxyolean-12-ene* (**7**; 146 mg; *t_R* 27.5 min), and *21β-angeloyloxy-3β,16α,28-trihydroxy-22α-(2-methylbutanoyloxy)olean-12-ene* (**8**; 125 mg; *t_R* 29.0 min), *Fr.* 3 (1000–1500 ml, 186 mg) was submitted to semi-prep. HPLC (*PRC-ODS*; MeOH/H₂O 90:10, at 2 ml/min) to give *21β-angeloyloxy-3β,16α,28-trihydroxy-22α-(2-methylbutanoyloxy)olean-12-en-23-al* (**3**; 21 mg; *t_R* 24.0 min) and *21β,22α-diangeloyloxy-3β,16α,28-trihydroxy-olean-12-en-23-al* (**4**; 136 mg; *t_R* 21.5 min). *Fr.* 4 (1500–2000 ml, 155 mg) was subjected to semi-prep. HPLC (*PRC-ODS* column; MeOH/H₂O 85:15, at 2 ml/min) to yield *22α-angeloyloxy-3β,15α,16α,28-tetrahydroxyolean-12-ene* (**9**; 111 mg; *t_R* 25.0 min). *Fr.* 5 (2000–2500 ml, 274 mg) was separated by to semi-prep. HPLC (*RC-ODS*; MeOH/H₂O 85:15, at 2 ml/min) to afford *22α-diangeloyloxy-3β,15α,16α,28-tetrahydroxyolean-12-ene* (**5**; 168 mg; *t_R* 17.0 min) and *21β-angeloyloxy-3β,15α,16α,28-tetrahydroxy-22α-(2-methylbutanoyloxy)olean-12-ene* (**6**; 26 mg; *t_R* 19.0 min). *Fr.* 5 (2500–3000 ml, 61 mg) was purified by semi-prep. HPLC (*PRC-ODS*; MeOH/H₂O 80:20, at 2 ml/min) to yield *21β,22α-diangeloyloxy-3β,15α,16α,28-tetrahydroxyolean-12-en-23-al* (**1**; 35 mg; *t_R* 25.5 min) and *21β-angeloyloxy-3β,15α,16α,28-tetrahydroxy-22α-(2-methylbutanoyloxy)olean-12-en-23-al* (**2**; 12 mg; *t_R* 27.0 min). The purity of the compounds was determined by anal. HPLC with PDA detection and ranged from 92% (for **2**) to 95% (for **5**).

(*3β,15α,16α,21β,22α*)-*3,15,16,28-Tetrahydroxy-23-oxoolean-12-ene-21,22-diyl (2Z,2'Z)-Bis(2-methylbut-2-enoate)* (= *21β,22α-Diangeloyloxy-3β,15α,16α,28-tetrahydroxyolean-12-en-23-al*; **1**). [α]_D²⁵ = +16.32 (*c* = 0.18, MeOH). IR (KBr): 3452, 2962, 2925, 2855, 2818, 2719, 1739, 1605, 1602, 1462, 1378, 1185, 1040. ¹H- and ¹³C-NMR: see *Table 1*. HR-ESI-MS (pos.): 707.4113 ([*M* + Na]⁺, C₄₀H₆₀NaO₇; calc. 707.4135).

(*3β,15α,16α,21β,22α*)-*3,15,16,28-Tetrahydroxy-22-[(2-methylbutanoyl)oxy]-23-oxoolean-12-en-21-yl (2Z)-2-Methylbut-2-enoate* (= *21β-Angeloyl-3β,15α,16α,28-tetrahydroxy-22α-(2-methylbutanoyloxy)olean-12-en-23-al*; **2**). [α]_D²⁵ = +18.16 (*c* = 0.16, MeOH). IR (KBr): 3475, 2960, 2922, 2853, 2820, 2719, 1742, 1720, 1600, 1460, 1375, 1168, 1047. ¹H- and ¹³C-NMR: see *Table 1*. HR-ESI-MS (pos.): 709.4270 ([*M* + Na]⁺, C₄₀H₆₂NaO₇; calc. 709.4292).

(*3β,16α,21β,22α*)-*3,16,28-Trihydroxy-22-[(2-methylbutanoyl)oxy]-23-oxoolean-12-en-21-yl (2Z)-2-Methylbut-2-enoate* (= *21β-Angeloyloxy-3β,16α,28-trihydroxy-22α-(2-methylbutanoyloxy)olean-12-en-*

23-*al*; **3**). $[\alpha]_D^{25} = +13.85$ ($c = 0.15$, MeOH). IR (KBr): 3450, 2958, 2920, 2850, 2820, 2720, 1738, 1722, 1603, 1462, 1381, 1176, 1038. ^1H - and ^{13}C -NMR: see *Table 1*. HR-ESI-MS (pos.): 693.4316 ($[M + \text{Na}]^+$, $\text{C}_{40}\text{H}_{62}\text{NaO}_8^+$; calc. 693.4342).

Cytotoxic Activity. To evaluate the cytotoxic activities of the triterpenoids from roots of *C. oleifera* against human HeLa, SMMC-7721, and HL-60 tumor cell lines (Cell Bank, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences), MTT (= 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*-tetrazolium bromide) colorimetric assay was performed [10]. The amount of formazan was determined by photometry at 570 nm. Cells were placed into 96-well flat-bottomed cultured plates at a concentration of 2×10^5 cells per well in complete RPMI 1640 culture medium. Twenty-four hours after plating, the medium containing foetal calf serum was removed, and test solns. were added to cells at concentrations of 2.5, 5, 10, 20, 50, and 100 μM . After incubation with drugs for 24 h, MTT soln. was added to the wells, and the plates were incubated at 37° for 4 h. The active control group was treated with norcantharidin (purity > 99.0% as determined by HPLC; *Nanjing Zelang Medical Technology Co., Ltd.*). The amount of formazan was determined by photometry at 540 nm. Results were expressed as percentage of the absorbance in control cells compared to that in the drug-treated cells. The IC_{50} values (50% inhibitory concentrations) of compounds **1–9** were compiled in *Table 2*.

REFERENCES

- [1] T. Takemoto, T. Miyasi, G. Kusano, *Phytochemistry* **1975**, *14*, 2534.
- [2] X. F. Cai, X. J. Jin, D. H. Lee, Y. T. Yang, K. Lee, Y. S. Hong, J. H. Lee, J. J. Lee, *J. Nat. Prod.* **2006**, *69*, 1095.
- [3] M. L. Oyarzún, J. A. Garbarino, V. Gambaro, J. Guilhema, C. Pascard, *Phytochemistry* **1986**, *26*, 221.
- [4] E. Aurada, J. Jurenitsch, W. Kubelka, *Sci. Pharm.* **1982**, *50*, 331.
- [5] P. K. Chan, *Biochem. Pharmacol.* **2007**, *73*, 341.
- [6] P. Wang, S. Ownby, Z. Z. Zhang, W. Yuan, S. Y. Li, *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2790.
- [7] L. Voutquenne, C. Kokougan, C. Lavaud, I. Pouny, M. Litaudon, *Phytochemistry* **2002**, *59*, 825.
- [8] Z. L. Li, X. Li, L. H. Li, N. Li, M. Yu, D. L. Meng, *Planta Med.* **2005**, *71*, 1068.
- [9] P. W. Khong, K. G. Lewis, *Aust. J. Chem.* **1976**, *29*, 1351.
- [10] Y. L. Liu, L. H. Tang, Z. Q. Liang, B. G. You, S. L. Yang, *J. Ethnopharmacol.* **2010**, *131*, 1.

Received June 30, 2012